Skip to content

#细胞治疗

Today 1 items
TodayOct 16Fri
  1. biopharmadive.com49

    Belgian startup revives Galapagos CAR-T research

    Lakefront Biotherapeutics, formerly Galapagos, has sold its cell therapy programmes to Belgian startup Armed Cell Therapeutics for 8 million euros up front, with up to $230 million more in future payments. The deal covers two armed CAR-T therapies nearing human testing in non-Hodkin lymphoma and small cell lung cancer, plus three undisclosed preclinical projects. Armed Cell named Willemijn Kremer, a former Galapagos cell therapy executive, as CEO, replacing interim CEO Paul Stoffels.

    Why it matters: Revives shelved CAR-T programmes under a new company after Galapagos wound down its cell therapy research.

Oct 15Thu
  1. biospace.com49

    Stoffels strikes up new biotech in return to Galapagos cell therapy mission

    Former Galapagos CEO Paul Stoffels has founded Armed Cell Therapeutics in Belgium to acquire the CAR T cell therapy programs that Galapagos, now Lakefront Biotherapeutics, abandoned in October 2025. Armed pays about $9 million upfront plus $230 million in milestones and royalties, just under $240 million in total, for the preclinical assets, which originated from AboundBio and target non-Hodgkin lymphoma and small cell lung cancer. Stoffels will chair the board, Willemien Kremer becomes CEO, and the company aims to move the programs into the clinic.

Oct 14Wed
  1. Nat Biotechnol82

    In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles.

    Ligand-directed lipid nanoparticles (NtLNPs) carrying mRNA transfected up to ~80% of NK cells in vivo in mice with minimal off-target effects, generating CAR NK cells without ex vivo engineering. CD19-targeted CAR NKs completely depleted circulating B cells in healthy mice, CD3-targeted CAR NKs eliminated nearly all autoreactive T cells in autoimmune hepatitis, and NKG2A-targeting versions improved solid tumor efficacy. Human-optimized NtLNPs produced CAR NK cells that regressed two humanized hematologic malignancy models. The work replaces viral, ex vivo CAR manufacturing with a modular in vivo mRNA delivery platform.

    Why it matters: It shows nonviral in vivo CAR NK generation, a route around ex vivo viral engineering of cell therapies.

  2. biocentury.com46

    Duracyte: Turning the patient into the bioreactor

    Duracyte, a Rice University spinout based in Houston, is developing subcutaneous implants of engineered human cells that continuously secrete biologics in the body for up to a year, with the aim of replacing repeated infusions and injections. The work has drawn roughly $120 million in non-dilutive funding. The company plans to start its first clinical trial in the first half of next year, testing an implant that produces the checkpoint inhibitor ipilimumab in patients with peritoneal cancer.

Oct 13Tue
  1. nature.com75

    In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles

    Ligand-directed lipid nanoparticles were used to engineer chimeric antigen receptor natural killer cells directly in vivo, an approach that avoids the ex vivo manufacturing central to current CAR cell therapies. The method targets NK cells with mRNA lipid nanoparticles carrying a ligand-directed delivery design. It moves CAR-NK immunotherapy toward a ready-to-administer, in-house production model.

    Why it matters: It shows CAR natural killer cells can be engineered inside the body rather than manufactured ex vivo.

  2. biopharmadive.com47

    Parkinson’s cell therapy developer files to go public

    Aspen Neuroscience, founded in 2018, has filed registration documents to list on the Nasdaq under ticker "ASPE" and would be the first Parkinson's-focused cell therapy developer to go public in the U.S. Its lead therapy sasineprocel, or ANPD001, reprograms a patient's own cells into dopamine-producing neurons and is entering late-stage testing after an early-stage trial. Aspen has raised about $347 million, posted a $62 million net loss in 2025 and nearly $37 million in the first six months of this year, and warned of substantial doubt about its ability to continue as a going concern without substantial additional capital.

Oct 12Mon
  1. Mult Scler41

    Autologous haematopoietic stem cell transplantation affects paramagnetic rim lesions in multiple sclerosis.

    Autologous haematopoietic stem cell transplantation was associated with a reduction in paramagnetic rim lesions, a marker of chronic inflammation that disease-modifying therapies barely affect. In 30 transplanted people with multiple sclerosis, PRL count decreased in 40% of PRL-positive cases scanned before and after AHSCT and in 57% of those scanned after only, with no new PRL appearing. Annualised PRL disappearance rates were -0.36 and -0.43, suggesting an effect on central nervous system microglia/macrophages.

Oct 11Sun
  1. Sci Adv77

    Extracellular matrix-targeted TNC-scFv armoring enhances CAR T cell persistence and antitumor activity in solid tumors.

    Armoring CAR T cells with a secreted tenascin-C-targeted single-chain variable fragment (TNC-scFv) enhanced cytotoxicity, persistence, and reduced exhaustion in vitro and in xenograft tumor models. Single-cell transcriptomics showed the approach reprograms the tumor microenvironment toward a CD8+ T cell-enriched, functionally active immune landscape, and humanized tumor models showed robust antitumor responses with minimal systemic toxicity. Combining the armoring with interleukin-2 further increased efficacy while mitigating cytokine-associated toxicity, establishing extracellular matrix-directed armoring as a generalizable strategy for solid tumors.

    Why it matters: It offers a generalizable armoring strategy that improves CAR T cell function against solid tumors, where efficacy has been limited.

Oct 10Sat
  1. Nat Med62

    Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.

    Extended follow-up of in vivo BCMA CAR-T (ESO-T01), given without leukapheresis or lymphodepletion to four patients with relapsed/refractory multiple myeloma, shows no new important adverse events beyond the initial report at up to 15 months. One patient maintained stringent complete response for 15 months; median progression-free survival was 4.0 months (range 3.0-15.0). Three patients relapsed or progressed, all with extramedullary involvement, and died during follow-up, indicating limited CAR-T persistence requiring platform optimization.

Oct 9Fri
  1. biopharmadive.com52

    In the hunt for reverse merger targets, Caribou could be prized game

    Caribou Biosciences, the CRISPR company co-founded by Jennifer Doudna, will stop developing its two off-the-shelf cell therapy programs for blood malignancies, citing a financing environment that CEO Rachel Haurwitz called increasingly challenging. The board has cleared management to evaluate a merger, acquisition or other transactions, with Wedbush Securities as exclusive financial advisor. Caribou ended the second quarter with $114 million in cash and securities, and Leerink analyst Daina Graybosch sees a reverse merger or a sale to Tang Capital as likely outcomes.

    Why it matters: A prominent CRISPR biotech with $114 million in cash is winding down and auctioning itself amid a wave of biotech reverse mergers.

Oct 8Thu
  1. biopharmadive.com65

    Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate

    Caribou Biosciences, the CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, is discontinuing research, laying off staff and seeking strategic alternatives after failing to raise money to advance its allogeneic CAR-T programs. The move ends work on vispa-cel, which was ready for Phase 3 testing in lymphoma with an FDA-agreed trial design, and CB-011, in testing for multiple myeloma. The board will weigh mergers, acquisitions or other transactions, with the workforce reduction mostly done by year-end.

Oct 7Wed
  1. biospace.com67

    Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up

    Caribou Biosciences, co-founded by CRISPR pioneer Jennifer Doudna, will end all R&D activities, halt its clinical trials and make substantial staff cuts after failing to secure financing for its allogeneic CAR-T programs, including vispa-cel for B cell non-Hodgkin lymphoma and CB-011 for multiple myeloma. The company, which had $113.8 million in cash as of June 30 and expects $15 million to $19 million in restructuring costs, will explore a merger, acquisition or other strategic transactions.

    Why it matters: Collapse of a well-funded allogeneic CAR-T developer signals how far financing has frozen in that field.

  2. statnews.com62

    STAT+: Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down

    Caribou Biosciences, the Berkeley, California CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, is shutting down after failing to raise the money needed for a late-stage trial of its off-the-shelf CAR-T therapy for lymphoma. CEO Rachel Haurwitz said the company had finalized the design of a Phase 3 trial for vispa-cel, its treatment for advanced B-cell non-Hodgkin lymphoma, with the FDA over the past year, but could not fund the study. Caribou will discontinue clinical development of both of its CRISPR-based CAR-T therapies.

  3. medicalxpress.com55

    International consensus sets updated framework for CAR T-cell therapy in severe autoimmune diseases

    A group of 31 international experts has published updated consensus recommendations in The Lancet Rheumatology on using CAR T-cell therapy for severe, treatment-refractory autoimmune diseases. The 2026 recommendations, developed by EBMT, ISCT and JACIE with input from EULAR and ECTRIMS, update the first best-practice guidance from 2024 and cover patient selection, treatment in experienced FACT/JACIE-accredited centers, and reporting of patient data to the EBMT Registry. The panel calls for treatment within clinical trials where possible and lists larger controlled trials, biomarkers and novel CAR targets as research priorities.

    Why it matters: New international guidance shapes how clinicians select and manage CAR T-cell patients in autoimmune disease, a fast-growing off-cancer use.

Oct 6Tue
  1. biorxiv.org50

    A long-term organotypic slice culture model of patient high-grade glioma preserving tumor heterogeneity and architecture, and specificity of CAR T cell targeting

    A patient-derived high-grade glioma organotypic slice culture (GOSC) platform preserved tumor histopathology, cell heterogeneity, microenvironment and architecture for at least 28 days in culture. Slices were grown under in situ-like conditions of 4% oxygen, 2.5 mM glucose and no added growth factors. GOSCs retained parental immunotherapy target expression, and CAR T cells showed target-specific killing in co-culture, supporting extended preclinical testing of therapeutics.

Oct 5Mon
  1. nature.com70

    Discovery and engineering of avian R2 retrotransposons for all-RNA-mediated targeted DNA integration in human cells

    Avian R2 retrotransposons were discovered and engineered as an all-RNA-mediated system for targeted DNA integration in human cells. Sequencing data from the work were deposited in the Genome Sequence Archive for Human under accession HRA013312, and the analytic code is publicly available on GitHub. The approach offers an RNA-only route to site-specific DNA insertion, in contrast to existing DNA-cleavage-based integration methods.

    Why it matters: A new avian R2 system extends all-RNA targeted DNA integration to human cells.

Oct 2Fri
  1. biocentury.com44

    Trio of biotechs draw nine-figure fundings: Public Equity Report

    Immix Biopharma (NASDAQ:IMIX) raised $125 million in an offering underwritten by J.P. Morgan, announced minutes after an interim readout from the Phase II NEXICART-2 trial showed its BCMA-targeted CAR-T therapy NXC-201 achieved an 89% complete response rate among 45 patients with light-chain (AL) amyloidosis. Immix plans a BLA submission next year, when final data from the study are expected. Sagimet and Pyxis Oncology also raised nine-figure sums, alongside an AstraZeneca/Summit item.

Sep 30Wed
  1. biospace.com45

    Atara, Pierre Fabre resubmit twice-rebuffed cell therapy after FDA flips again

    Atara Biotherapeutics and Pierre Fabre Pharmaceuticals have resubmitted the BLA for Ebvallo (tabelecleucel) to treat EBV-positive posttransplant lymphoproliferative disease in patients 2 years and older, after two complete response letters, the second in January. The FDA reversed course in May, agreeing a single-arm study with an appropriate historical control could support approval. The resubmission adds patients and longer follow-up from the Phase 3 ALLELE trial plus expanded access, separate study and European commercial data; a Class 2 resubmission could carry a March 29, 2027 action date, and Atara is eligible for a $31 million milestone on approval.

  2. Sci Adv62

    Tumor cell-intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer.

    Tumor cell-intrinsic oxidative and proteotoxic stress pathways modulate response to CAR T cell therapy in pancreatic ductal adenocarcinoma. Using in vivo CRISPR screens, single-cell genomics and immunocompetent orthotopic PDAC models, disruption of stress regulatory genes, especially Keap1 and Slc33a1, sensitized tumors to CAR T cell killing in vivo. Clinically observed Keap1 or Nfe2l2 mutations, and Keap1 loss activating the Nrf2 pathway, likewise increased susceptibility, suggesting tumor genotype could stratify patients for CAR T cell therapy.

    Why it matters: Identifies tumor stress genotype as a predictor of CAR T response, enabling patient stratification in solid tumors.

Sep 23Wed
  1. Nature Medicine64

    Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy

    Enterocolitis after BCMA CAR-T cell therapy in patients with multiple myeloma is driven not only by plasma cell and B cell depletion but by expansion of cytotoxic CAR-T cells and coordinated dysregulation across intestinal compartments, a multimodal analysis shows. Mucosal CAR-T cells persist at the inflammation site. The findings support JAK inhibitors as a potential treatment for this complication.

    Why it matters: Redefines the mechanism of BCMA CAR-T enterocolitis and points to JAK inhibitors as a treatment option.

Sep 15Tue
  1. Cancer Cell65

    Depletion of an immature cord blood NK subset reverses trogocytosis-driven CAR NK dysfunction.

    An immature CD16-CD161- double-negative cord blood NK subset drives CAR NK product dysfunction: after CAR engineering these cells remained hypofunctional yet showed exaggerated trogocytosis, forming a trogocytic-antigen sink that diverted CAR engagement from tumors and caused exhaustion, fratricide and death of CD16+CD161+ double-positive effectors. Depleting the DN subset before manufacturing eliminated the antigen sink and restored antitumor activity in hematologic and solid tumor models. The work converts donor heterogeneity into an actionable manufacturing step for more potent off-the-shelf CAR NK products.

    Why it matters: It identifies a donor subset-driven mechanism of CAR NK dysfunction and a simple pre-manufacturing depletion that restores potency.

Sep 11Fri
  1. Nat Biotechnol70

    Selective RNA sequestration in biomolecular condensates directs cell fate transitions.

    P-bodies selectively sequester translationally repressed, untranslated RNAs encoding cell fate regulators in a conserved, cell type-specific manner across vertebrate developmental contexts. P-body RNA contents are controlled by microRNAs and reshaped by perturbing AGO2 or polyadenylation site usage. Manipulating P-body assembly or microRNA activity directed naive mouse and human pluripotent stem cells toward totipotency and primed human embryonic cells toward the germ cell lineage.

    Why it matters: It identifies RNA condensate manipulation as a practical method for steering pluripotent stem cell fate.

Sep 10Thu
  1. Nature67

    Efficient and precise programmable DNA knock-in without double-strand breaks.

    CRISPR kilobase-scale nickase-targeting (KNIT) editing inserts DNA fragments from 0.7 kb to over 10 kb without double-strand DNA cleavage by coupling a Cas9 nickase with a DNA donor recruiting system. It achieves up to 89% efficiency, cuts indel rates, translocations and off-target editing, restores gene expression in mutant cells, and enables non-viral CAR-T engineering with antitumour activity in vitro and in mice. This shifts kilobase-scale knock-in away from double-strand-break editing.

    Why it matters: A break-free CRISPR method reaching 89% knock-in efficiency could change how cell therapies are engineered.

  2. biocentury.com45

    BrainChild: Bringing CAR Ts directly to the brain

    BrainChild Bio Inc. of Seattle and Cambridge, Mass., raised $116 million in series A financing backed by Seattle Children's Research Institute and WRF Capital, with an undisclosed family fund leading. The company delivers CAR T cells directly into the cerebrospinal fluid rather than the bloodstream, aiming to allow repeat dosing for CNS cancers while avoiding systemic toxicities seen in other CAR T programs. Targets include B7-H3, EGFR and IL-13RA2.

    Why it matters: New financing backs a repeat-dose intrathecal CAR T approach for CNS cancers.

Sep 8Tue
  1. Cell44

    Basement membrane turnover controls cell shape.

    Basement membrane stress relaxation time can regulate 3D cell shape, according to mathematical modeling. Molecular dynamics simulations show the stress relaxation time of a collagen IV network can be inferred from collagen IV molecule lifetime, and a new fluorescent timer reporter measures that lifetime in vivo, revealing that perlecan modifies it. The work establishes a multiscale framework linking matrix turnover to cell shape control.

Sep 7Mon
  1. Cell55

    Localized PD-1 CAR T therapy reprograms neuroinflammation.

    A single-cell RNA sequencing atlas of CSF, brain and blood from MS patients and controls identified a rare, disease-enriched subset of activated PD-1+ T follicular helper-like cells with B cell-recruiting features. PD-1-directed CAR T cells selectively depleted pathogenic PD-1+ CD4 T cells and locally released IL-10, attenuating CNS inflammation and improving clinical outcomes in murine neuroinflammation models. The work defines a CNS-localized adaptive immune circuit in MS and proposes programmable PD-1 CAR T cells to disrupt it.

    Why it matters: It nominates a CNS-localized PD-1 CAR T strategy against a newly defined immune circuit in MS.

Sep 5Sat
  1. Mol Cell55

    ER-liquid condensate contacts sequester FAM134B/C and RhoA to govern cell morphology.

    ER-phagy receptors FAM134B/C have a non-canonical role beyond ER remodeling: an amphipathic helix in FAM134B binds PRKAR1A dimers at contact sites between the ER and liquid-like PRKAR1A condensates. These contacts promote clustering of FAM134B/C with LC3B and recruit lysosomes, forming degradation hubs that sequester RhoA. In mouse pancreatic ductal adenocarcinoma cells, this cAMP-responsive pathway controls cell morphology and migration.

Sep 4Fri
  1. Nat Biotechnol61

    Integrated epigenetic and genetic programming of primary human T cells.

    An all-RNA platform using CRISPRoff and CRISPRon epigenetic editors stably turns endogenous genes off or on in primary human T cells without sustained CRISPR expression. Silencing persists through cell divisions, T cell stimulations and in vivo adoptive transfer, without the cytotoxicity or chromosomal abnormalities of multiplexed Cas9 editing. Combined Cas12a-dCas9 engineering enabled CAR knock-in plus gene silencing, improving preclinical CAR-T tumor control and survival.

Sep 2Wed
  1. Nat Med59

    Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial.

    Allogeneic human induced pluripotent stem cell-derived cardiomyocytes injected into the myocardium during CABG met the safety primary endpoint in the HEAL-CHF trial (n = 20): no sustained ventricular tachycardia in the 1- to 6-month window and no tumorigenicity at 12 months. All 10 cell-treated patients developed accelerated idioventricular rhythm within 4 weeks, and 2 had ventricular tachycardia over 140 bpm that resolved after cardioversion. Cell therapy improved 6-min walk distance, myocardial perfusion and relative wall thickening beyond CABG alone, but not ejection fraction, ventricular volumes, scar size, NYHA class or quality-of-life scores.

    Why it matters: First randomized evidence on safety and early efficacy of allogeneic hiPSC-derived cardiomyocyte injection in ischemic heart failure.

  2. Sci Immunol50

    CAR T cell-derived TNF is an early determinant of cytokine release syndrome severity.

    CAR T cell-derived TNF drives cytokine release syndrome severity by acting upstream of host inflammation. Disrupting TNF signaling in a mouse model of CRS prevented accumulation of pro-inflammatory monocyte-derived macrophages at the tumor site and blocked induction of host cytokines IL-6 and IL-1β. In humanized xenochimeras, TNF determined overall disease course including lethality.

Sep 1Tue
  1. Cell66

    Expansion and CAR engineering of granulocyte-monocyte progenitors for cellular immunotherapy.

    Defined culture conditions allow long-term ex vivo expansion of mouse and human granulocyte-monocyte progenitors (GMPs) while preserving progenitor identity, with myeloperoxidase identified as a regulator of GMP proliferation. After transfer, engineered GMPs seed hematopoietic niches, restore antibacterial defense in chronic granulomatous disease mice, and generate tumor-infiltrating macrophages. CAR-engineered GMPs suppress CD19-positive leukemia and HER2-positive solid tumors, including in immunocompetent allogeneic models using a CAR with an IgG Fc domain.

    Why it matters: It establishes expandable GMPs as a renewable platform for CAR myeloid cell therapy across liquid and solid tumors.

  2. aacrjournals.org61

    First CAR T-Cell Therapy Approved for Solid Tumors

    China has approved satricabtagene autoleucel (satri-cel), the first CAR T-cell therapy for solid tumors, for patients with claudin 18.2-positive, HER2-negative gastric or gastro-esophageal junction cancer. The approval is based on a phase II trial showing improved progression-free and overall survival. Scientists welcome the decision but say more research is needed to improve CAR T-cell effectiveness against solid tumors.

    Why it matters: First regulatory approval of a CAR T-cell therapy for a solid tumor indication.

Aug 28Fri
  1. Nat Biotechnol72

    Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells.

    A virus-like particle toolkit delivers CRISPR ribonucleoproteins to human monocytes, macrophages and dendritic cells, supporting gene knockout, base editing, epigenetic silencing and, with AAV donor delivery, site-specific integration by homology-directed repair. SLICeVLP, pairing VPX-lentivirus sgRNA delivery with VLP Cas9 delivery, enabled pooled loss-of-function and Perturb-seq screens in human macrophages. Screens converged on TNFAIP3 as a central regulator of inflammatory polarization; its ablation produced a proinflammatory state resistant to suppressive repolarization and enhanced CAR-macrophage cytotoxicity.

    Why it matters: It provides scalable CRISPR editing and pooled screening in primary human myeloid cells, where such tools were limited.

  2. nature.com71

    Precise genomic integration of large DNA fragments by donor-directed annealing using prime editing

    Prime assembly (PA) uses prime editing to create complementary 3' single-stranded DNA flaps on genome and donor, enabling double-strand-break-free megabase-scale genomic excision and multikilobase donor insertion in human cells. The system achieved 57.8% replacement efficiency at endogenous loci with multikilobase payloads, and in primary human T cells it integrated a chimeric antigen receptor site-specifically with up to 28.1% efficiency. It offers precise simultaneous large-scale deletion and insertion where existing DSB-based and recombinase-based methods fall short.

    Why it matters: It enables double-strand-break-free kilobase-scale gene replacement in human cells, including primary T cells, with efficiencies no existing system reaches.

Aug 27Thu
  1. Nat Med50

    CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.

    A single infusion of mivocabtagene autoleucel, a fully human CD19 CAR T cell therapy, depleted CD19+ B cells in blood and tissue of six patients with severe, treatment-refractory, ACPA-positive rheumatoid arthritis after lymphodepletion. CRS occurred in all six but was limited to grade 1 and 2, with no ICANS or serious adverse events. Disease activity improved in all patients off immunosuppression, with a median 34% DAS28-CRP reduction, DAS28-CRP remission and ACR70 response in 3 of 6, and ACPA seroconversion in 4 of 6. The primary safety endpoint was met, allowing advancement to phase 2.

Aug 25Tue
  2. Lancet62

    Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial.

    Intravenous deramiocel, a heart-derived cellular therapy, slowed disease progression in advanced Duchenne muscular dystrophy in the phase 3 HOPE-3 trial. Among 106 participants aged 10 years or older, total Performance of the Upper Limb 2.0 percentage change at 12 months significantly favoured deramiocel over placebo, with a safety profile similar to placebo. Quarterly outpatient infusions preserved skeletal muscle function regardless of the underlying genetic lesion.

    Why it matters: Phase 3 evidence that a quarterly outpatient cell infusion slows upper limb function loss in advanced DMD.

  3. Nature86

    In vivo genome-wide CRISPR screens of human T cells in solid tumours.

    Genome-wide in vivo CRISPR screens of human T cells in solid tumours identify two GPCR-related targets: the P2RY8-Gα13 axis limits T cell tumour infiltration, and GNAS drives T cell dysfunction, with Gαs acting as a convergent node downstream of multiple suppressive GPCRs. GNAS knockout made T cells resistant to suppressive cues and improved efficacy in CAR and TCR models across diverse solid tumours, and combined P2RY8-GNAS knockout further enhanced tumour control.

    Why it matters: It provides an in vivo screening platform and identifies knockout targets that improve CAR and TCR T cell therapy in solid tumours.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org